2025-12-04 - Analysis Report
Okay, here's a breakdown of Hims & Hers Health Inc. (HIMS) stock based on the data provided, with analysis:

**0. Report Setup**

*   **Ticker:** HIMS
*   **Company Name:** Hims & Hers Health Inc

**1. Return Rate vs. S&P 500 (VOO)**

*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that offers personalized health and wellness solutions directly to consumers.
*   **HIMS Cumulative Return:** 134.36%
*   **VOO Cumulative Return:** 74.53%
*   **Divergence:** 82.8
*   **Relative Divergence:** 41.4

**Analysis:** HIMS has significantly outperformed the S&P 500. The cumulative return is much higher, but the relative divergence of 41.4 indicates it's currently in the lower half of its historical divergence range compared to the S&P 500. This suggests that while HIMS has done well overall, recent performance hasn't pushed it to the top of its divergence history.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
|------------|---------|--------|---------|--------|--------|
| 2019-2021  | -42.0%  | 74.4%  | -81.0%  | 0.0    | 1.5    |
| 2020-2022  | -19.0%  | 78.6%  | -18.0%  | -0.0   | 1.5    |
| 2021-2023  | -65.0%  | 78.6%  | -67.0%  | -0.1   | 2.0    |
| 2022-2024  | 119.0%  | 79.4%  | 98.0%   | -0.0   | 5.5    |
| 2023-2025  | 139.0%  | 80.8%  | 74.0%   | 0.1    | 8.3    |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate shows volatile performance. The negative CAGRs in the earlier periods turned sharply positive in the most recent periods.
*   **MDD:** Maximum Drawdown is consistently high, indicating significant risk and volatility.
*   **Alpha:** Alpha is a measure of performance on a risk-adjusted basis. The alpha is negative in the early stages, suggesting HIMS underperformed relative to its risk. However, in the recent periods, alpha is strongly positive, indicating outperformance.
*   **Beta:** Beta is very close to zero, suggesting HIMS's price is relatively independent of the market, which is unusual. It means HIMS hasn't closely followed the broader market's movements.
*   **Cap(B):** Market capitalization has steadily increased, reflecting company growth.

**2. Recent Stock Price Fluctuations**

*   **Close:** 36.3
*   **Last-market:** {'price': 36.325, 'previousClose': 36.31, 'change': 0.04}
*   **5-day SMA:** 37.69
*   **20-day SMA:** 38.30
*   **60-day SMA:** 47.99

**Analysis:**  The stock price is currently below all three moving averages (5-day, 20-day, and 60-day). This suggests a potential downtrend in the short to medium term. The slight difference between the last price and the previous close indicates minimal movement in the most recent trading session.

**3. RSI, PPO, and Other Indicators**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 41.51 (Below 50, indicating potential weakness)
*   **PPO:** 1.06 (Positive but relatively low, suggesting a slight upward trend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 7.5 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** 18.1%

**Analysis:**

*   **MRI:** The Market Risk Indicator is high, suggesting the model considers this a good time to invest, but take it with caution.
*   **RSI:** The RSI is below 50, which is not yet in oversold territory (typically below 30) but indicates downward momentum.
*   **PPO:** A positive PPO suggests the shorter-term moving average is above the longer-term moving average, implying an upward trend.
*   **Hybrid Signal:** The signal suggests using all available cash to buy HIMS stock, which is labelled as "Very Safe" due to the high MRI.
*   **Divergence Change:** The recent increase in relative divergence suggests short-term positive momentum.
*   **Expected Return:** An 18.1% expected return is attractive if held for over two years, implying the model forecasts significant growth.

**4. Recent News & Significant Events**

*   **Share Repurchase Program:** Hims & Hers announced a $250 million share repurchase program, which is generally seen as a positive sign, indicating the company believes its stock is undervalued.
*   **Stock Plunge:** News highlights a 15.6% drop in the stock price over 3 months.
*   **Acquisition of YourBio Health:** Hims & Hers acquired YourBio Health for blood sampling technology. This expands their offerings and could be a positive strategic move.
*   **Analyst Opinions:** Coverage of Q3 earnings and market challenges.

**Analysis:** The news is mixed. The share repurchase program and acquisition are positive developments. However, the reported stock price decline and coverage of market challenges suggest some investor concerns.

**4-2. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 3.00 (Hold)
*   **Opinions:** 11
*   **Target Price (avg/high/low):** 44.82 / 85.00 / 25.00
*   **Recent Rating Changes:** Not provided.

**Analysis:** The analyst consensus is "Hold," indicating a neutral outlook on the stock. The average target price is $44.82, which is higher than the current price of $36.30, suggesting some upside potential. The wide range of target prices (25.00 to 85.00) reflects significant uncertainty among analysts.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-11-03 | 0.07 | 0.60 B$  |
| 2025-08-04 | 0.19 | 0.54 B$  |
| 2025-05-05 | 0.22 | 0.59 B$  |
| 2024-11-04 | 0.35 | 0.40 B$  |
| 2025-11-03 | 0.35 | 0.40 B$  |

**Analysis:**

*   Revenue shows a general upward trend.
*   EPS (Earnings Per Share) fluctuates, with a recent decline in the most recent period (2025-11-03). The EPS dropped in the last period, even though sales are strong, so the cost may be the issue.

**6. Financial Information**

Revenue and Profitability:

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.60B  | 73.80%        |
| 2025-06-30   | $0.54B  | 76.39%        |
| 2025-03-31   | $0.59B  | 73.50%        |
| 2024-12-31   | $0.48B  | 76.81%        |
| 2024-09-30   | $0.40B  | 79.16%        |

Capital and Profitability:

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-09-30   | $0.58B  | 2.72%    |
| 2025-06-30   | $0.56B  | 7.55%    |
| 2025-03-31   | $0.55B  | 9.01%    |
| 2024-12-31   | $0.48B  | 5.46%    |
| 2024-09-30   | $0.44B  | 17.18%   |

**Analysis:**

*   **Revenue:** Revenue has been growing steadily, demonstrating increasing sales.
*   **Profit Margin:** Profit margins are generally high, indicating good cost control and pricing power. However, the margins have seen some fluctuation.
*   **Equity:** Equity has been increasing, demonstrating the company's growing net worth.
*   **ROE:** Return on Equity (ROE) has fluctuated and decreased more recently.

**7. Comprehensive Analysis (Summary)**

Hims & Hers Health Inc. (HIMS) presents a mixed picture:

*   **Positive:** HIMS has significantly outperformed the S&P 500 in cumulative return. The acquisition of YourBio Health and share repurchase program are positive catalysts. Revenue is growing, and profit margins are generally strong. The MRI suggests a favorable investment opportunity, and the hybrid signal points to a "buy" recommendation.
*   **Negative:** The stock price is currently below key moving averages, suggesting a short-term downtrend. News highlights a recent stock price decline. The analyst consensus is "Hold," indicating a neutral outlook. ROE has decreased recently. The company's high MDD and volatile CAGR indicates significant risk and volatility.
*   **Overall:** HIMS is a high-growth, but volatile stock. The company's recent strategic moves and growth in revenue are encouraging. However, investors should be aware of the risks associated with its volatility, recent price decline, and fluctuating profitability metrics. The stock appears to be a speculative buy with significant upside potential, but also significant downside risk. Further investigation into the reasons behind the recent EPS decline and ROE contraction is warranted before making an investment decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.